Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X:
“Sequencing absolutely matters in metastatic EGFR+ NSCLC.
Even with advances like combination therapy, 26–31% of these often younger, fit patients with EGFR+ disease never make it to 2L treatment.”
More from WCLC25 on OncoDaily.